Pharma Q2 Earnings Preview - Elevated Price Erosion Could Impact Business In U.S.: Axis Securities
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Axis Securities Report
We expect, pharma universe could report high single digit growth (8.1% YoY), majorly driven by injectables and generic segment.
India pharma market grew by 16% that is driven by a volume bounce back and recovery in sales of non Covid-19 products.
In U.S., we expect prices competition still persists in generic segment that could limit the growth in last quarter.
Currency appreciation could improve the topline by 1.5% on YoY basis.
Generic companies like Dr. Reddy Laboratories Ltd. and Lupin Ltd. could report 5.6% & 3.0% YoY topline growth in Q2 FY22E.
In overall, earnings for the pharma universe would moderate and come in flat YoY, after seven quarters of healthy performance.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.